TABLE 2

Microdomain variants resulting in significant loss of antibody bindinga

Peptide namebPeptide sequencecBoLA-DRβ3 haplotyping
SM.StM2 Md-1GKGEGSNGTKK
VP.StM2-1.1d-KGTGSTGT-K(*0601, *1001)(*0101, *2703)(*0902, *1101)
VP.StM2-1.2d-KGTGTGSDGTKK
SM.G11 Md-1KGTGSTGSSGNK
VP.G11-1.1d-GKG-TGSTGTT(*0601, *1001)(*0101, *2703)(*0902, *1101)
VP.G11-1.2d-GNG-TGSTGTT
VP.G11-1.3dKGTG-TDSSGNK
VP.G11-1.4d-GNG-TSGTGGTQ
SM.9H1 Md-2KNSGDTNGSSTTQH
VP.9H1-2.1dKNSGDTSGS-TTQH(*0103, *0101)(*0101, *2703)(*0902, *1101)
SM.E6/F7 Md-2KNTTDSTNNNG
VP.E6F7-2.1KNTTDGTT---(*0103, *0101)(*0101, *2703)(*0902, *1101)
VP.E6F7-2.2dKNTADGTTATT
VP.E6F7-2.3dKNTADGTT---
VP.E6F7-2.4dKNTADGNATTQR-
VP.E6F7-2.6dKNATSGT-AQTNG
VP.E6F7-2.9d---T-GTAGATT
SM.StM1 Md-2VNATSGSTNNG
VP.StM1-2.1VNATSGSTNNNG(*0103, *0101)(*0601, *1001)(*0902, *1101)
VP.StM1-2.3dVNATSG-TATT
VP.StM1-2.4VNATSGTAQTN-G
VP.StM1-2.8dVD-T-GNTNNNG
VP.StM1-2.9dVNATSGTAAQTN-G
VP.StM1-2.10VNATSGTAQT---
VP.StM1-2.11VNATSGTAQR---
VP.StM1-2.12dVNAASGTTAQT---
VP.StM1-2.14dVNATSGTTT----
  • a Variant peptides that resulted in a significant decrease in antibody recognition, defined as binding that was statistically significantly less than binding to the homologous St. Maries strain peptide in all biological replicates.

  • b Boldface indicates the parent St. Maries strain homologous peptide; VP indicates the specific variant peptide as defined in Fig. 2 and 3.

  • c Italics indicate insertions relative to the parent St. Maries sequence, dashes indicate deletions, and underlining indicates substitutions.

  • d Variant peptide that resulted in complete ablation of antibody binding in at least one biological replicate.